Cargando…

Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis: Specnuezhenide suppresses diabetes-induced bone loss

Diabetes osteoporosis is a chronic complication of diabetes mellitus (DM) and is associated with osteoclast formation and enhanced bone resorption. Specnuezhenide (SPN) is an active compound with anti-inflammatory and immunomodulatory properties. However, the roles of SPN in diabetic osteoporosis re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Xiaoshuang, Jiang, Juanjuan, Yang, Juan, Yan, Wenyan, Jiang, Luyue, Chen, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827798/ https://www.ncbi.nlm.nih.gov/pubmed/35929595 http://dx.doi.org/10.3724/abbs.2022094

Ejemplares similares

Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss
por: Qi, Dahu, et al.
Publicado: (2021)

Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
por: Liu, Hui, et al.
Publicado: (2021)

Parkin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss
por: Hou, Weiduo, et al.
Publicado: (2022)

BCI Suppresses RANKL-Mediated Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
por: Cai, Chenhui, et al.
Publicado: (2021)

Specnuezhenide Decreases Interleukin-1β-Induced Inflammation in Rat Chondrocytes and Reduces Joint Destruction in Osteoarthritic Rats
por: Ma, Chiyuan, et al.
Publicado: (2018)

Inhibition of Hypoxia-Induced Retinal Angiogenesis by Specnuezhenide, an Effective Constituent of Ligustrum lucidum Ait., through Suppression of the HIF-1α/VEGF Signaling Pathway
por: Wu, Jianming, et al.
Publicado: (2016)

Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo
por: Peng, Jiaxuan, et al.
Publicado: (2020)

The Molecular Mechanisms Study of Engeletin Suppresses RANKL-Induced Osteoclastogenesis and Inhibits Ovariectomized Murine Model Bone Loss
por: Feng, Mingzhe, et al.
Publicado: (2023)

Gut microbiota-based pharmacokinetic-pharmacodynamic study and molecular mechanism of specnuezhenide in the treatment of colorectal cancer targeting carboxylesterase
por: Yu, Hang, et al.
Publicado: (2023)

Theaflavin-3, 3′-Digallate Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Ovariectomy-Induced Bone Loss in Mice
por: Ai, Zexin, et al.
Publicado: (2020)

Evodiamine inhibits RANKL‐induced osteoclastogenesis and prevents ovariectomy‐induced bone loss in mice
por: Jin, Haiming, et al.
Publicado: (2018)

Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
por: Zhan, Yunfei, et al.
Publicado: (2020)

Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis
por: Chen, Xiao, et al.
Publicado: (2017)

Tetrandrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-Induced Osteoclastogenesis
por: Zhong, Zeyuan, et al.
Publicado: (2020)

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
por: Jin, Haiming, et al.
Publicado: (2019)

Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
por: Qi, Guobin, et al.
Publicado: (2022)

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2021)

Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss
por: Zhang, Yong, et al.
Publicado: (2015)

Lactulose Suppresses Osteoclastogenesis and Ameliorates Estrogen Deficiency-Induced Bone Loss in Mice
por: Chen, Xiao, et al.
Publicado: (2019)

Inhibition of PFKFB3 suppresses osteoclastogenesis and prevents ovariectomy‐induced bone loss
por: Wang, Jia, et al.
Publicado: (2019)

Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption
por: Niu, Chenguang, et al.
Publicado: (2017)

Specnuezhenide Ameliorates Age-Related Hepatic Lipid Accumulation via Modulating Bile Acid Homeostasis and Gut Microbiota in D-Galactose-Induced Mice
por: Deng, Xuehui, et al.
Publicado: (2023)

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2023)

Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL‐induced osteoclastogenesis
por: Qian, Zhi, et al.
Publicado: (2020)

Physalin D inhibits RANKL-induced osteoclastogenesis and bone loss via regulating calcium signaling
por: Ding, Ning, et al.
Publicado: (2020)

Umbelliferone Prevents Lipopolysaccharide-Induced Bone Loss and Suppresses RANKL-Induced Osteoclastogenesis by Attenuating Akt-c-Fos-NFATc1 Signaling
por: Kwak, Sung Chul, et al.
Publicado: (2019)

IGFBP7 acts as a negative regulator of RANKL‐induced osteoclastogenesis and oestrogen deficiency‐induced bone loss
por: Ye, Chenyi, et al.
Publicado: (2019)

Tectorigenin inhibits RANKL‐induced osteoclastogenesis via suppression of NF‐κB signalling and decreases bone loss in ovariectomized C57BL/6
por: Ma, Chiyuan, et al.
Publicado: (2018)

Rapamycin Inhibits Osteoclastogenesis and Prevents LPS-Induced Alveolar Bone Loss by Oxidative Stress Suppression
por: Feng, Chong, et al.
Publicado: (2023)

The PPAR-γ antagonist T007 inhibits RANKL-induced osteoclastogenesis and counteracts OVX-induced bone loss in mice
por: Li, Xiang, et al.
Publicado: (2019)

Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR
por: Huang, Jun-ming, et al.
Publicado: (2018)

Pharmacological inhibition of protein S-palmitoylation suppresses osteoclastogenesis and ameliorates ovariectomy-induced bone loss
por: Ma, Linghui, et al.
Publicado: (2023)

Andrographolide Inhibits Ovariectomy-Induced Bone Loss via the Suppression of RANKL Signaling Pathways
por: Wang, Tao, et al.
Publicado: (2015)

Corilagin suppresses RANKL‐induced osteoclastogenesis and inhibits oestrogen deficiency‐induced bone loss via the NF‐κB and PI3K/AKT signalling pathways
por: Lu, Jinwei, et al.
Publicado: (2020)

Casticin suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating the AKT/ERK and NF-κB signaling pathways
por: Yang, Fan, et al.
Publicado: (2023)

PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice
por: Choi, Joo-Hee, et al.
Publicado: (2018)

Madecassoside inhibits estrogen deficiency‐induced osteoporosis by suppressing RANKL‐induced osteoclastogenesis
por: Wang, Qingqing, et al.
Publicado: (2018)

Correction to “Rapamycin Inhibits Osteoclastogenesis and Prevents LPS-Induced Alveolar Bone Loss by Oxidative Stress Suppression”
por: Feng, Chong, et al.
Publicado: (2023)

Fermented Oyster Extract Prevents Ovariectomy-Induced Bone Loss and Suppresses Osteoclastogenesis
por: Ihn, Hye Jung, et al.
Publicado: (2019)

Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis
por: Wang, Yabing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c22div8naosajbgegftfdjep1f